NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics to Present at Biotech Showcase 2023
A Revolution in Treating Autoinflammatory & Orphan Diseases
Akari TX /
NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics to Present at Biotech Showcase 2023
Akari TX /
CLICK TO READ ENTIRE TRANSCRIPT With the reach and impact of biopharma growing exponentially, experts in biotech and the evolving regulatory environment came …
Akari TX /
NEW YORK and LONDON, December 1, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
Akari TX /
Ticks aren’t all bad! Check out the Business of Biotech podcast to hear how Akari engineered #nomacopan, a recombinant protein derived from ticks, and scaled …
[Read more...] about Akari on the Business of Biotech podcast
Akari TX /
NEW YORK and LONDON, November 22, 2022(GLOBE NEWSWIRE) - Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics to Participate in the Ophthalmology Day at BTIG
75/76 Wimpole Street London W1G 9RT UK
T: +44 (0)20.8004.0261
E: info@Akaritx.com
1460 Broadway
New York, NY 10036
T: 929.274.7510
F: 929.274.7553
E: info@Akaritx.com
For investor relations inquiries: IR@akaritx.com
For business development inquiries: BD@akaritx.com
Akari Therapeutics, Plc is registered in England and Wales under number 5252842 and has its registered office at Highdown House, Yeoman Way, Worthing, West Sussex, BN99 3HH.
In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.